Sunshine Biopharma, Inc.
SBFM
$1.48
$0.085.71%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.42M | 9.41M | 8.90M | 9.60M | 8.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.42M | 9.41M | 8.90M | 9.60M | 8.44M |
| Cost of Revenue | 6.34M | 5.99M | 6.17M | 6.50M | 5.57M |
| Gross Profit | 3.07M | 3.42M | 2.73M | 3.09M | 2.87M |
| SG&A Expenses | 3.27M | 4.03M | 3.64M | 4.81M | 3.73M |
| Depreciation & Amortization | 95.80K | 72.50K | 64.80K | 65.40K | 64.60K |
| Other Operating Expenses | 119.90K | 112.70K | 110.20K | 108.80K | 56.50K |
| Total Operating Expenses | 9.95M | 10.40M | 10.20M | 11.63M | 9.54M |
| Operating Income | -532.00K | -992.80K | -1.30M | -2.04M | -1.11M |
| Income Before Tax | -1.02M | -1.98M | -1.22M | -2.29M | -982.60K |
| Income Tax Expenses | -137.40K | -209.20K | -40.20K | -128.70K | 215.20K |
| Earnings from Continuing Operations | -883.80K | -1.77M | -1.18M | -2.16M | -1.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -883.80K | -1.77M | -1.18M | -2.16M | -1.20M |
| EBIT | -532.00K | -992.80K | -1.30M | -2.04M | -1.11M |
| EBITDA | -435.80K | -920.30K | -1.23M | -1.97M | -1.04M |
| EPS Basic | -0.19 | -0.39 | -0.44 | -1.00 | -0.95 |
| Normalized Basic EPS | -0.06 | -0.13 | -0.28 | -0.66 | -0.48 |
| EPS Diluted | -0.19 | -0.39 | -0.44 | -1.00 | -0.95 |
| Normalized Diluted EPS | -0.06 | -0.13 | -0.28 | -0.66 | -0.48 |
| Average Basic Shares Outstanding | 4.56M | 4.50M | 2.70M | 2.15M | 1.27M |
| Average Diluted Shares Outstanding | 4.56M | 4.50M | 2.70M | 2.15M | 1.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |